Literature DB >> 25171927

Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.

Noel F C C de Miranda1, Konstantinos Georgiou1, Longyun Chen2, Chenglin Wu1, Zhibo Gao2, Apostolos Zaravinos1, Susana Lisboa3, Gunilla Enblad4, Manuel R Teixeira3, Yixin Zeng5, Roujun Peng5, Qiang Pan-Hammarström6.   

Abstract

Next-generation sequencing studies on diffuse large B-cell lymphomas (DLBCLs) have revealed novel targets of genetic aberrations but also high intercohort heterogeneity. Previous studies have suggested that the prevalence of disease subgroups and cytogenetic profiles differ between Western and Asian patients. To characterize the coding genome of Chinese DLBCL, we performed whole-exome sequencing of DNA derived from 31 tumors and respective peripheral blood samples. The mutation prevalence of B2M, CD70, DTX1, LYN, TMSB4X, and UBE2A was investigated in an additional 105 tumor samples. We discovered 11 novel targets of recurrent mutations in DLBCL that included functionally relevant genes such as LYN and TMSB4X. Additional genes were found mutated at high frequency (≥10%) in the Chinese cohort including DTX1, which was the most prevalent mutation target in the Notch pathway. We furthermore demonstrated that mutations in DTX1 impair its function as a negative regulator of Notch. Novel and previous unappreciated targets of somatic mutations in DLBCL identified in this study support the existence of additional/alternative tumorigenic pathways in these tumors. The observed differences with previous reports might be explained by the genetic heterogeneity of DLBCL, the germline genetic makeup of Chinese individuals, and/or exposure to distinct etiological agents.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25171927      PMCID: PMC4199956          DOI: 10.1182/blood-2013-12-546309

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.

Authors:  René Scholtysik; Inga Nagel; Markus Kreuz; Inga Vater; Maciej Giefing; Carsten Schwaenen; Swen Wessendorf; Lorenz Trümper; Markus Loeffler; Reiner Siebert; Ralf Küppers
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.

Authors:  J Iqbal; T C Greiner; K Patel; B J Dave; L Smith; J Ji; G Wright; W G Sanger; D L Pickering; S Jain; D E Horsman; Y Shen; K Fu; D D Weisenburger; C P Hans; E Campo; R D Gascoyne; A Rosenwald; E S Jaffe; J Delabie; L Rimsza; G Ott; H K Müller-Hermelink; J M Connors; J M Vose; T McKeithan; L M Staudt; W C Chan
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

Review 4.  Regulation of innate and adaptive immunity by Notch.

Authors:  Freddy Radtke; H Robson MacDonald; Fabienne Tacchini-Cottier
Journal:  Nat Rev Immunol       Date:  2013-05-13       Impact factor: 53.106

5.  Human deltex is a conserved regulator of Notch signalling.

Authors:  K Matsuno; D Eastman; T Mitsiades; A M Quinn; M L Carcanciu; P Ordentlich; T Kadesch; S Artavanis-Tsakonas
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

6.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.

Authors:  L Pasqualucci; P Neumeister; T Goossens; G Nanjangud; R S Chaganti; R Küppers; R Dalla-Favera
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

7.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

8.  High-resolution mapping of copy-number alterations with massively parallel sequencing.

Authors:  Derek Y Chiang; Gad Getz; David B Jaffe; Michael J T O'Kelly; Xiaojun Zhao; Scott L Carter; Carsten Russ; Chad Nusbaum; Matthew Meyerson; Eric S Lander
Journal:  Nat Methods       Date:  2008-11-30       Impact factor: 28.547

9.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

10.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.

Authors:  Laura Pasqualucci; Mara Compagno; Jane Houldsworth; Stefano Monti; Adina Grunn; Subhadra V Nandula; Jon C Aster; Vundavally V Murty; Margaret A Shipp; Riccardo Dalla-Favera
Journal:  J Exp Med       Date:  2006-02-20       Impact factor: 14.307

View more
  52 in total

1.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.

Authors:  Hiroshi Arima; Momoko Nishikori; Yasuyuki Otsuka; Wataru Kishimoto; Kiyotaka Izumi; Koubun Yasuda; Tomohiro Yoshimoto; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2018-09-25

Review 2.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 3.  Germinal centres and B cell lymphomagenesis.

Authors:  Katia Basso; Riccardo Dalla-Favera
Journal:  Nat Rev Immunol       Date:  2015-03       Impact factor: 53.106

4.  Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Authors:  Solène M Evrard; Sarah Péricart; David Grand; Nadia Amara; Frédéric Escudié; Julia Gilhodes; Pierre Bories; Alexandra Traverse-Glehen; Romain Dubois; Pierre Brousset; Marie Parrens; Camille Laurent
Journal:  Haematologica       Date:  2018-10-11       Impact factor: 9.941

5.  Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant.

Authors:  Shamzah Araf; Jun Wang; Margaret Ashton-Key; Koorosh Korfi; Doriana Di Bella; Ana Rio-Machin; Mariette Odabashian; Vipul Foria; Ming-Qing Du; Francesco Cucco; Sharon Barrans; Peter Johnson; Sophie R Laird; Andrew M Fisher; Jonathan O Cullis; Trevor A Graham; Jessica Okosun; Jude Fitzgibbon; Laura Chiecchio
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

Review 6.  Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Authors:  Richard Rosenquist; Andreas Rosenwald; Ming-Qing Du; Gianluca Gaidano; Patricia Groenen; Andrew Wotherspoon; Paolo Ghia; Philippe Gaulard; Elias Campo; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

7.  Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.

Authors:  Leo Meriranta; Annika Pasanen; Riku Louhimo; Alejandra Cervera; Amjad Alkodsi; Matias Autio; Minna Taskinen; Ville Rantanen; Marja-Liisa Karjalainen-Lindsberg; Harald Holte; Jan Delabie; Rainer Lehtonen; Sampsa Hautaniemi; Sirpa Leppä
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941

8.  Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C.

Authors:  Alex J Cornish; Phuc H Hoang; Sara E Dobbins; Philip J Law; Daniel Chubb; Giulia Orlando; Richard S Houlston
Journal:  Blood Adv       Date:  2019-01-08

9.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Authors:  Weicheng Ren; Xiaofei Ye; Hong Su; Wei Li; Dongbing Liu; Mohammad Pirmoradian; Xianhuo Wang; Bo Zhang; Qiang Zhang; Longyun Chen; Man Nie; Yao Liu; Bin Meng; Huiqiang Huang; Wenqi Jiang; Yixin Zeng; Wenyu Li; Kui Wu; Yong Hou; Klas G Wiman; Zhiming Li; Huilai Zhang; Roujun Peng; Shida Zhu; Qiang Pan-Hammarström
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

10.  Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.

Authors:  Michelle J Lee; Jean L Koff; Jeffrey M Switchenko; C Ileen Jhaney; R Andrew Harkins; Sharvil P Patel; Sandeep S Dave; Christopher R Flowers
Journal:  Cancer       Date:  2020-05-29       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.